Goldman Sachs Assumes Cytokinetics (CYTK) at Buy
Get Alerts CYTK Hot Sheet
Price: $39.04 +0.75%
Rating Summary:
17 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 21 | New: 12
Rating Summary:
17 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 21 | New: 12
Trade Now!
Join SI Premium – FREE
Goldman Sachs analyst Madhu Kumar assumes coverage on Cytokinetics (NASDAQ: CYTK) with a Buy rating and a price target of $74.00.
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $29.74 yesterday.
You May Also Be Interested In
- UPDATE: Stephens Starts CyberArk Software (CYBR) at Overweight
- Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
- Needham & Company Assumes Axon Enterprise (AXON) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!